Among the growing number of patients with heart failure, as many as half have heart failure with preserved ejection fraction (HFpEF). In this condition the signature symptoms relate to relaxation abnormality in diastole, which limit the cardiac output due to comprimised ventricular filling. To date, clinical trials have yet to find an effective and specific treatment for this condition. Our studies utilise our unique experimental models of HFpEF to investigate the underlying functional, cellular and molecular changes that occur with HFpEF and aims to identify therapeutic targets for this disease. We work with clinical partners in developing specialized imaging methods to benchmark laboratory derived measures of diastolic dysfunction against patient characteristics.